Hosted by Professor Craig Underhill, Dr Kate Clarke & Professor Christopher Jackson | Proudly produced by The Oncology Network
Kate Clarke takes over hosting duties!
Join our expert trio — Professor Craig Underhill, Dr Kate Clarke and Professor Christopher Jackson — for the usual OJC antics in Part 2 of our ESMO Special.
Craig talks us through the GU and lung highlights, while the team each share their top ‘practice-changing’ abstracts. Plus, CJ chats with Susie Stanway about the upcoming London Global Cancer Week.
Expect nuanced analysis, sharp insights and the occasional cheeky joke along the way.
About The Oncology Journal Club:
We have taken an old concept and updated it with a new format. In each episode, a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.
We hope you enjoy listening and find this a valuable and entertaining resource.
BINGO CARD: Download here
ABSTRACTS:
Craig:
Guo, J., et al. LBA7 – Disitamab vedotin (DV) plus toripalimab (T) versus chemotherapy (C) in first-line (1L) locally advanced or metastatic urothelial carcinoma (la/mUC) with HER2-expression. ESMO Congress 2025. LBA7 – Access online here.
Vulsteke, C., et al. LBA2 – Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study. ESMO Congress 2025. LBA2 – Access online here.
Freedland, S., et al. LBA87 – EMBARK: Overall survival with enzalutamide in biochemically recurrent prostate cancer. ESMO Congress 2025. LBA87 – Access online here.
Wermke, M., et al. 2757O – Tarlatamab with first-line chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC): DeLLphi-303 study. ESMO Congress 2025. 2757O – Access online here.
Lu, S., et al. LBA4 – Phase III study of ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer (HARMONi-6). ESMO Congress 2025. LBA4 – Access online here.
Zhang, L., et al. LBA5 – Sacituzumab tirumotecan (sac-TMT) vs platinum-based chemotherapy in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) following progression on EGFR-TKIs: results from the randomized, multi-center phase III OptiTROP-Lung04 study. ESMO Congress 2025. LBA5 – Access online here.
Nowak, A., et al. LBA104 Primary results of DREAM3R: DuRvalumab (MEDI4736) with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma: A phase III randomised trial. ESMO Congress 2025. LBA104 – Access online here.
Dziadziuszko, R., et al. LBA69 – SKYSCRAPER-03: Phase III, open-label, randomised study of atezolizumab (atezo) + tiragolumab (tira) vs durvalumab (durva) in locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) after platinum-based concurrent chemoradiation (cCRT). ESMO Congress 2025. LBA69 – Access online here.
OTHER RESOURCES MENTIONED:
S3E8 The Oncology Journal Club ESMO Special Part 1
TEAM:
Craig Underhill
Professor Craig Underhill
Professor Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.
In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.
Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.
You can find Craig on X/Twitter here: @CraigUnderhill
Kate Clarke
Dr. Kate Clarke
Dr Kate Clarke (MBChB (Otago), FRACP) is a proud New Zealander with a real love for beautiful Aotearoa. Dr Clarke continues to work at being Tangata Tiriti. Much of her research and patient advocacy has an equity focus. Dr Clarke is grateful to her patients, students, whanau and colleagues for the knowledge and awhi they share. Ehara taku toa, he takitahi, he toa takitini.
Dr Clarke completed her medical training in Otago, Wellington and London. She has a holistic approach and is passionate about patient-centred care, and believes patients can and should play an active role in their healthcare. Her clinical experience covers a broad range of solid tumour malignancies with special clinical interest in colorectal cancer, upper gastrointestinal cancers and breast cancer.
Chris ‘CJ’ Jackson
Professor Christopher Jackson
Chris Jackson is Professor of Medical Oncology at the University of Otago, Dunedin, and a medical oncologist at Dunedin Hospital and Mercy Cancer Care. He specialises in GI cancers and melanoma, teaches medical students and specialists-in-training, and is heavily involved in both national and international cancer policy, leadership and research.
He was previously the medical director of the Cancer Society of NZ, and his advocacy led to the funding of new cancer drugs, to the development of a new national cancer plan, and to the birth of the national cancer agency Te Aho o Te Kahu. He currently chairs the agency’s clinical committee and serves on the advisory board. In addition, he is on the programme board of the International Cancer Benchmarking Project, and is a founding member of the Common Sense Oncology movement.
Chris is a self-confessed Radiohead tragic, and recent convert to Crossfit (even though you didn’t ask).
Connect with CJ on X/Twitter: @drkiwicj
PRODUCER:
Rachael Babin
Rachael Babin is Host of The Oncology Podcast, Editor-in-Chief of The Oncology Newsletter, and Publisher of Oncology News Australia and The Oncology Network.
With a background in oncology communications and academic publishing, Rachael is happiest sitting behind the mic chatting to interesting people about the impact their work makes in oncology.
Connect on Twitter: @OncologyNewsAus
